Brief: Humacyte Acellular Tissue Engineered Vessel Receives FDA's Regenerative Medicine Advanced Therapy Designation For Patients With Advanced Peripheral Artery Disease
01/07/2024 13:13
July 1 (Reuters) - Humacyte Inc HUMA.O :
* HUMACYTE ACELLULAR TISSUE ENGINEERED VESSEL (ATEV™)
RECEIVES
FDA’S REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION
FOR PATIENTS WITH ADVANCED PERIPHERAL ARTERY DISEASE (PAD)
Source text for Eikon: ID:nGNX2RWFjg
Further company coverage: HUMA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Humacyte
See all newsBrief: Humacyte Announces Lancet Digital Health Publication Of V007 Phase 3 Hemodialysis Access Trial Results
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte
Humacyte falls after wider-than-expected quarterly loss
Humacyte Inc reports results for the quarter ended June 30 - Earnings Summary